BOOK A DEMO

Sonic Incytes Selected for RESI Innovator’s Pitch Challenge

Sonic Incytes Medical Corp., the developer of VelacurTM, has been selected to participate in the Innovator’s Pitch Challenge at the upcoming Redefining Early Stage Investments (RESI) conference, held digitally June 8-10, 2021.

The Innovator’s Pitch Challenge is an opportunity for early-stage companies to gain additional exposure to conference attendees and pitch directly to a panel of relevant investors.

Sonic Incytes CEO George Aliphtiras will present VelacurTM, the first handheld 3D liver health assessment solution to tackle the emerging fatty liver disease (NASH) crisis, on June 8.

The RESI conference connects start-ups with early-stage investors and strategic channel partners, who are a fit for their technology and stage of development.

For more information, visit https://resiconference.com/pitch-challenge/.

Sync up

with Sonic

Be in-the-know on all our latest news!

Subscribe to our e-newsletter.

Julia PinterMarketing Director

Julia Pinter brings over a decade of medical technology marketing experience spanning product commercialization, launch strategy, and sales enablement. Prior to joining Sonic Incytes, she served as Director of Global GI Product Marketing at PENTAX Medical, where she led global downstream marketing for the company’s largest portfolio — driving commercial launches of next-generation endoscopes, imaging systems, and AI platforms across the Americas, Europe, and Asia-Pacific. At Sonic Incytes, Julia leads downstream marketing initiatives to expand awareness and accelerate adoption of Velacur One®, translating its clinical and economic value into programs that support broader adoption of non-invasive liver assessment.